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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A335Methods: Primary care patients with unilateral clinical and radio-
graphic hip OA, participating in a randomized clinical trial, recorded at
baseline pain intensity using an 11-box numeric rating scale, pain
duration in months and the distribution of hip pain using a manikin
displaying three separate views: front, back and lateral. Pain drawings
were analysed using a template to determine pain locations and dis-
tribution of pain. Drawings were subsequently digitally processed to
produce a composite image using colours to illustrate frequency.
Results: A total of 108/109 (99%) patients completed pain drawings
according to instructions. One drawing consisted of a single line but the
identiﬁed areas were included in the analyses of pain location and the
composite image. The mean age was 65 (SD 9), 44% were females, the
right/left hip ratio was 66/43 respectively, the mean pain duration was
32 months (SD 36, range 4e300), and mean pain intensity was 5.4 (SD
2.0). A total of 77% had marked the area of the greater trochanter, 53%
the groin, 42% the anterior/lateral thigh, 38% the buttock, 17% the knee
and 15% the lower leg. Less than 20% of the patients reported pain in
only one area, most commonly the greater trochanter area (16%).
Between 1-2% of the patients reported pain only at the groin, buttock or
anterior/lateral thigh. No patients marked pain exclusively in the areas
of the knee, posterior thigh or lower leg. The composite images of the
cumulated pain drawings in the three planes are illustrated in Figure 1.
Conclusions: To our knowledge, this is the ﬁrst study describing pain
location and distribution in a cohort of patients presenting to primary
care with hip pain and unilateral hip OA. In descending order, the most
common pain locations are the greater trochanter, groin, thigh and
buttock areas. No patients with hip OA reported pain exclusively in the
knee or to the lower leg areas. When adult patients in primary care
present with pain in the greater trochanter, groin, anterior lateral thigh
or buttock areas, the clinician as a minimum should include a physical
examination of the hip joint.
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CONCERNS IMPORTANT TO ELDERLY PATIENTS WITH HAND
OSTEOARTHRITIS: A QUALITATIVE MULTI-ETHNIC ASIAN STUDY
Y.Y. Leung y, W. Li z, J. Thumboo y. y Singapore Gen. Hosp., Singapore,
Singapore; zDuke-NUS Graduate Med. Sch. Singapore, Singapore,
Singapore
Purpose: Hand osteoarthritis (HOA) is common but little is known
about how to measure the impact on disability and quality of life (QoL)
among patients with HOA. None of the existing HOA speciﬁc instru-
ments was patients-derived. With the ageing population, there is a
need to develop instruments in patients' perspective for measuring
disability and QoL for use in future drug trials. We aim to identify
important concerns among patients suffering from symptomatic HOA
in Singapore. It is the ﬁrst study with participation of patients from the
Asian socio-cultural context.
Methods: A qualitative study using a focus group technique was per-
formed. Patients with symptomatic HOA according to American college
of Rheumatology Classiﬁcation criteria were recruited from outpatient
clinic of a tertiary centre. Focus groups were conducted as stratiﬁed by
gender, ethnicity and language. All discussions were audio-taped and
analyzed in an inductive approach. Areas of concern important to study
participants were then compared to the following commonly used HOA
speciﬁc instruments: FIHOA, SACRAH, AUSCAN and HAQ.
Results: Twenty-six patients [23 women, 3 men; 23 Chinese and 3
Malay; mean (SD) age 62.9 (7.5) years] participated in seven focusgroups. Two and ﬁve focus groups were conducted in Chinese and
English respectively. The qualitative analysis revealed detailed
descriptions of pain sensations at different qualities, and its relation to
activity and environment, none of which were fully represented in the
existing instruments. Psychological consequences, aesthetic concerns,
participation in leisure activities, participation in family roles and social
activities are important concerns from the focus groups which were not
covered by the existing instruments. Important QoL concerns that
impact on the Asian style of living including eating, cooking and praying
was revealed. Impact on work productivity by HOA was also revealed.
Out of the 59 concerns among patients with HOA, only 16 concerns
(27%) were covered with the existing instruments.
Conclusions: The concerns important to HOA patients are not fully
represented in the most commonly used instruments, which were not
patient-derived. This qualitative study helps to reﬁne the concerns of
people with HOA in patients' perspectives. It gives information on
selection of domains for the development of instrument that measure
QoL of HOA patients.
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THE ROLE OF сYTOKINES IN PATIENTS WITH OSTEOARTHRITIS AND
TYPE 2 DIABETES MELLITUS
M. Oliinyk. Kharkov Natl. Med. Univ., Kharkov, Ukraine
Purpose: to investigate inﬂuence of concentration in plasma tumor
necrosis factor-a (TNF-a), interleukin-1b (IL-1b) on articular syndrome
and parameters of carbohydrate metabolism in patients with osteo-
arthritis (OA) and type 2 diabetes mellitus (T2DM).
Methods: The study was performed on 65 patients (29 males), aged
57.9 ± 3.2 with combination OA and T2DM in Regional Hospital of
Kharkov. Baseline characteristics of patients included history of OA (7.1
± 2.3 years), T2DM (8.1 ± 2.5 years). All patients were divided into 2
groups: group 1 (n¼ 30) ewith combined course of OA and T2DMwith
normal body weight, group 2 (n ¼ 35) e with combined course of OA
and T2DM with obesity (BMI 30 kg/m2). The survey plan included:
anthropometric data, indices of carbohydrate exchange (insulin, glu-
cose, HbA1C, HOMA-IR) and level of C-reactive protein (CRP). The level
of HbA1C was <7.5% in all patients. The level of TNF-a and IL-1b was
determined by ELISA. All patients were made X-ray examination of
knees.
Results: Signiﬁcant correlation between TNF-a and CRP was deter-
mined in 1st group (r¼0.59; р<0.05) and 2nd group (r¼0.72; р<0.05),
also correlation between IL-1b and CRP was determined in 1st group
(r¼0.61; р<0.05) and 2nd group (r¼0.78; р<0.05). Among the 1st group
of patients the level of insulin resistance was correlated with TNF-a
(r¼0.36; р<0.05) and IL-1b (r¼0.42; р<0.05). More signiﬁcant correla-
tion between TNF-a and glucose (r¼0.44; р<0.05), HbA1C (r¼0.54;
р<0.05), insulin resistance (r¼0.74; р<0.05), HOMAIR (r¼0.63; р<0.05)
and between IL-1b and glucose (r¼0.42; р<0.05), HbA1C (r¼0.40;
р<0.05), insulin resistance (r¼0.52; р<0.05), HOMAIR (r¼0.50; р<0.05)
was determined in 2nd groupwith comorbid pathology and obesity. We
noticed, the degree of X-ray changes (by Kellgren-Lawrence) were more
in 2nd group in compare with the 1st group.
Conclusions: Signiﬁcant correlation between TNF-a, IL-1b and CRP,
glucose, НbА1, insulin resistance, HOMA-IR in group of patients with
comorbid pathology and obesity means, that obesity is important factor
of pathogenesis relationship immune and metabolic processes in
patients with OA and T2DM.
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SOLUMATRIX DICLOFENAC SAFETY IN OLDER PATIENTS WITH
OSTEOARTHRITIS PAIN
R.D. Altman y, M. Hochberg z, A. Gibofsky x, P. Tenzer k, C.L. Young ¶.
yDavid Geffen Sch. of Med., Univ. of California Los Angeles, Los Angeles,
CA, USA; zUniv. of Maryland Sch. of Med., Baltimore, MD, USA; xHosp.
for Special Surgery, New York, NY, USA; kUniv. of Miami Miller Sch. of
Med., Miami, FL, USA; ¶ Iroko Pharmaceuticals, Philadelphia, PA, USA
Purpose: SoluMatrix® diclofenac is a low-dose nonsteroidal anti-
inﬂammatory drug (NSAID) treatment option developed using Sol-
uMatrix Fine Particle Technology™ to provide effective analgesia at
lower doses than commercially available diclofenac drug products.
SoluMatrix diclofenac was developed to address concerns regarding the
risks for dose-related adverse events (AEs) that have led health
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SoluMatrix diclofenac is approved for the management of mild to
moderate acute pain and osteoarthritis (OA) pain in adults. Based on
previous studies that examined the efﬁcacy and safety of SoluMatrix
diclofenac, we evaluated the pooled safety of SoluMatrix diclofenac in
older patients (65 years of age) across two phase 3 studies.
Methods: A 12-week randomized, multicenter, double-blind, parallel-
group study enrolled 305 chronic NSAID and/or acetaminophen users,
41 to 90 years of age with symptomatic and radiographically docu-
mented (Kellgren-Lawrence grade II or III) OA of the hip or knee.
Patients had baseline Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain subscale scores 40 mm at base-
line and a documented OA pain “ﬂare” (increase in WOMAC pain sub-
scale 15 mm) following NSAID/acetaminophen discontinuation.
Patients received either SoluMatrix diclofenac capsules 35 mg two or
three times daily (BID or TID) or placebo. A 12-month open-label,
multicenter study treated 601 chronic NSAID/acetaminophen users,
aged 40 to 86 years, with knee and/or hip OA. Patients initially received
SoluMatrix diclofenac 35-mg capsules BID; that could be increased to
TID and reduced as needed.
Results: Similar proportions of patients reported AEs in the 65 years
of age group (157/205 [76.6%]) compared with the <65 years of age
group (365/500 [73.0%]). In patients 65 years of age treated with
SoluMatrix diclofenac, the most commonly reported AEs included
nausea (18/205, 8.8%), diarrhea (17/205, 8.3%), and upper respiratory
tract infection (17/205, 8.3%). In patients <65 years of age treated with
SoluMatrix diclofenac, the most commonly reported AEs were head-
ache (40/500, 8.0%), upper respiratory tract infection (34/500, 6.8%),
and diarrhea (32/500, 6.4%). Forty-six of the 205 patients 65 years of
age (22.4%) withdrew from the study due to any AE, whereas 73/500
patients <65 years of age (14.6%) withdrew from the study due to an AE.
Few SoluMatrix diclofenac-treated patients experienced AEs reported
in class labeling for NSAIDs, including stroke, myocardial infarction,
gastrointestinal ulcers, perforation or hemorrhage, or liver function
abnormalities and occurred with no major differences among the two
age groups (Table). Two patients (<65 years of age) reportedmyocardial
infarctions, which were not considered to be treatment-related; there
were no deaths.Conclusions: In pooled 12-week and 12-month phase 3 studies, a
comparable proportion of SoluMatrix diclofenac-treated patients 65
years of age and <65 years of age experienced similar AEs. These data
add to the growing SoluMatrix diclofenac safety experience.
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BMI, PAIN AND FUNCTION IN PATIENTS WITH KNEE
OSTEOARTHRITIS
N.L. Brito, A.E. Rosales, M.U. Rezende, R. Fruchi, G.C. Campos, A.F. Pailo.
Inst. de Ortopedia e Traumatologia e HC FMUSP, S~ao Paulo, Brazil
Purpose: To evaluate the relationship between BMI and pain and
function in patients with knee osteoarthritis (KOA) undergoing multi-
professional clinical treatment.
Methods: Thirty-eight patients (four men and 34 women) aged 47-83
years old (mean 63.2 years) in usual treatment for knee OA for more
than three months, i.e. oral diacerhein and analgesics (according to
pain), orthotics (when indicated) were selected for a two-days two
months apart multiprofessional (medical, nutritional, psychological,
physical and occupational therapy, physical educator and social work-
ers) educational program on Ostearthritis. X-rays were performed to
classify the OA degree (Kelgreen & Lawrence e K&L). All patients were
evaluated at baseline (one month prior to ﬁrst class) and at 6 months (3
months after the second class) with height, weight (BMI estimation),
and asked to complete WOMAC, Lequesne, and visual analogue pain
scale questionnaires.
Results: Eight patients had grade I (K&L), eleven, grade II, thirteen,
grade III and six, grade IV. The results regarding change in VAS,
WOMAC-pain, WOMAC and Lequesne did not correlate to the initial
degree of osteoarthritis. There was no signiﬁcant BMI variation in this
study (average -0.2, SD¼ 0.22, range -4.9, 2.7). The higher the initial
BMI, the lower the improvement in pain (Spearman test, p ¼ 0.03). Pain
did not improve signiﬁcantly (p¼ 0.2). Function improved (p <0.001) in
inverse ratio to the initial BMI. However, the group that decreased BMI
tended to improve pain and function and the group that increased BMI
tended to improve pain and function (Kruskal-Wallis test, not
signiﬁcant).
Conclusions: BMI determines how patients will improve pain and
function.
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GENDER DIFFERENCES IN THE RELATIONS BETWEEN CLINICAL
QUESTIONNAIRES AND RADIOGRAPHIC GRADES IN KNEE
OSTEOARTHRITIS. A CROSS-SECTIONAL EVALUATION OF 518
PATIENTS
A. Herman y,z, A. Mor x, O. Chechik k, G. Segal x, Y. Kosashvili ¶,
R. Lador k, M. Salai k, A. Elbaz x, A. Haim k. y Sheba Med. Ctr., Tel
Hashomer, Israel; z Tel-Aviv Univ., Tel Aviv, Israel; xApos Med. and Sports
Technologies, Herzliya, Israel; k Sourasky Med. Ctr., Tel Aviv, Israel;
¶Rabin Med. Ctr., Petah Tikve, Israel
Purpose: To evaluate the correlations between common clinical OA
diagnostic tools in order to determine the value of each. A secondary
goal was to investigate the inﬂuence of gender differences on the
ﬁndings.
Methods: Five hundred and eighteen patients with knee OA were
evaluated using the Western Ontario and McMaster Osteoarthritis
Index (WOMAC) questionnaire, short form 36 (SF-36) Health Survey
and plain radiographs. Analysis of variance (ANOVA) was used to
compare the different domains of the WOMAC and SF-36 ques-
tionnaires between genders and the radiographic scale.
Results: Higher knee OA x-ray grade were associated with worse clin-
ical outcome: for womene higher scores for theWOMAC pain, function
and ﬁnal scores and lower scores in the SF-36 ﬁnal score; in men: lower
SF-36 overall and Physical domains scores. Gender differences were
found in all clinical scores that were tested, with women having worse
clinical scores for similar radiographic grading (p values< 0.001).
Conclusions: Knee radiographs for OA have an important role in the
clinical evaluation of the patient. Patients with higher levels of knee OA
in x-ray has a higher probability of having a worse clinical score in the
WOMAC and SF-36 scores. The gender differences suggest that for
similar knee OA x-ray grade women's clinical scores are lower.
